Saxenda shows positive weight loss and cardiometabolic risk factors in 3-year study

Danish diabetes care giant Novo Nordisk (NOV: N) has released three-year data showing early response to Saxenda (liraglutide) resulted in improvements in weight loss and cardiometabolic risk factors.

The data from a post hoc analysis of the three-year part of the Phase IIIa SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016) yesterday.

Adults with prediabetes and obesity or who were overweight with co-morbidities were randomised to receive Saxenda (n=1,505) or placebo (n=749) for 160 weeks, both as an adjunct to a reduced-calorie diet and increased physical activity. People treated with Saxenda who lost 5% or more of their body weight at 16 weeks (classified as 'early responders') demonstrated greater weight loss and improvements in cardiometabolic risk factors at week 160 compared with those who lost less than 5% of their body weight at 16 weeks ('early non-responders').